Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Duloxetine in SSRI Non-Responders
NCT00191932Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of duloxetine in major depressive disorder (MDD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hamilton Rating Scale for Depression (17-item) at 10 weeks. Started Aug 2004; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00191932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191932.